Inflammation Resolution: Implications for Atherosclerosis

Doran, Amanda C.

doi:10.1161/circresaha.121.319822

Cited by 86 publications

(45 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As early as the 19th century, pathologists Rokitansky and Virchow described the in ammatory characteristics of atherosclerotic plaques (Grebe et al, 2018). In recent years, multiple clinical studies have con rmed that the residual risk after traditional LDL-lowering therapy is mainly due to in ammation (Doran, 2022). According to the Canakinumab Anti-in ammatory Thrombosis Outcome Study (CANTOS), lowering low-grade systemic in ammation in CVD patients reduced the risk of acute cardiovascular events without affecting blood cholesterol levels (Ridker et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice

Wang

Zhao

Ding

et al. 2022

Preprint

View full text Add to dashboard Cite

Oridonin, a well-known traditional Chinese herbal medicinal product isolated from Isodon rubescens (Hemsl.) H.Hara, has many potential properties, including anti-inflammatory and antioxidant activities. However, there is no evidence whether oridonin have a protective effect on atherosclerosis. This study focused on the effects of oridonin on oxidative stress and inflammation generated from atherosclerosis. The therapeutic effect on atherosclerosis was evaluated by intraperitoneal injection of oridonin in a high-fat fed ApoE−/− mouse model. We isolated mouse peritoneal macrophages and detected the effect of oridonin on oxidized low-density lipoprotein-induced lipid deposition. Oil red O staining, Masson's staining, Dihydroethidium (DHE) fluorescence staining, Immunohistochemical staining, western blotting analysis, immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and quantitative real-time PCR were used to evaluate the effect on atherosclerosis and explore the mechanisms. Oridonin treatment significantly alleviated the progression of atherosclerosis, reduced macrophage infiltration and stabilized plaques. Oridonin could significantly inhibit inflammation associated with NLRP3 activation. Oridonin significantly reduced oxidative stress by blocking Nrf2 ubiquitination and degradation. We also found that oridonin could prevent the formation of foam cells by increasing lipid efflux protein and reducing lipid uptake protein in macrophages. Oridonin has a protective effect on atherosclerosis in ApoE−/− mice, which may be related to the inhibition of NLRP3 and the stabilization of Nrf2. Therefore, oridonin may be a potential therapeutic agent for atherosclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice

Wang

Zhao

Ding

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In many animal studies, SPMs have been shown to reduce plaque progression and some human studies also suggest a link between SPMs and ASCVD. A comprehensive review of the contribution of the inflammatory resolution, or lack thereof, to ASCVD was recently published by Doran [ 28 ]. SPMs have specific receptors that can promote inflammation or resolution depending upon the ligand binding to them.…”

Section: Inflammation In Cardiovascular Diseasementioning

confidence: 99%

“…Other emerging areas of research regarding how inflammation contributes to ASCVD include air and noise pollution, reduced and/or interrupted sleep, and other stressors [ 28 ]. These relationships open the door to considering how other methods of lifestyle modification could protect against ASCVD.…”

Section: Inflammation In Cardiovascular Diseasementioning

confidence: 99%

Immune Cell Activation in Obesity and Cardiovascular Disease

et al. 2022

View full text Add to dashboard Cite

Purpose of Review In this review, we focus on immune cell activation in obesity and cardiovascular disease, highlighting specific immune cell microenvironments present in individuals with atherosclerosis, non-ischemic heart disease, hypertension, and infectious diseases. Recent Findings Obesity and cardiovascular disease are intimately linked and often characterized by inflammation and a cluster of metabolic complications. Compelling evidence from single-cell analysis suggests that obese adipose tissue is inflammatory and infiltrated by almost all immune cell populations. How this inflammatory tissue state contributes to more systemic conditions such as cardiovascular and infectious disease is less well understood. However, current research suggests that changes in the adipose tissue immune environment impact an individual’s ability to combat illnesses such as influenza and SARS-CoV2 . Summary Obesity is becoming increasingly prevalent globally and is often associated with type 2 diabetes and heart disease. An increased inflammatory state is a major contributor to this association. Widespread chronic inflammation in these disease states is accompanied by an increase in both innate and adaptive immune cell activation. Acutely, these immune cell changes are beneficial as they sustain homeostasis as inflammation increases. However, persistent inflammation subsequently damages tissues and organs throughout the body. Future studies aimed at understanding the unique immune cell populations in each tissue compartment impacted by obesity may hold potential for therapeutic applications.

show abstract

“…Unresolved inflammation has been proven to play a causal role in the onset of CVD [ 12 ]. As such, a clear understanding of these endogenous inflammatory processes is critical to pinpoint the cause behind the continuous nonresolution of cardiovascular inflammation [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

Salazar

Pirela

Nava

et al. 2022

IJMS

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.

show abstract

Inflammation Resolution: Implications for Atherosclerosis

Cited by 86 publications

References 182 publications

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice

Oridonin attenuates the progression of atherosclerosis by inhibiting NLRP3 and activating Nrf2 in apolipoprotein E-deficient mice

Immune Cell Activation in Obesity and Cardiovascular Disease

Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis

Contact Info

Product

Resources

About